SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure amid reports of a board investigation into CEO Jensen Huangs alleged affair with a woman suspected of ties to Chinese intelligence, with traders debating whether the controversy could threaten his leadership or involve export-control breaches; those allegations remain unproven. Some see the selloff as an overreaction and are buying the dip ahead of earnings, while others cite governance and China-related uncertainty as reasons to sell or wait.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts AI data-center spending and reported pullbacks from some third-party cloud and expansion deals are driving debate over whether the company is tightening execution or signaling weaker AI demand. Bears point to heavy capex, financing needs and data-center delays as risks to cash flow, while bulls see the moves as a shift toward newer capacity and a more disciplined buildout.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,110,071. The last known price of Bitcoin is 74,895.40905656 USD and is down -0.28 over the last 24 hours. It is currently trading on 12776 active market(s) with $26,892,693,016.04 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins selloff is drawing attention as hotter-than-expected U.S. inflation strengthens fears of further Fed rate hikes, with traders also pointing to leveraged-position liquidations and broken technical support. The community is split between expecting more downside and viewing the pullback as a buying opportunity, with some looking for a bounce near key support levels.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportan unexpected loss, weaker profitability guidance, margin pressure and a sequential subscriber declinehas driven HIMS sharply lower. Bearish traders question whether growth can translate into profits, while bulls see an oversold buying opportunity and point to the planned Peptides+ launch as a potential growth catalyst.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A quarterly earnings beat and stronger-than-expected outlook sparked a sharp rally, but shares gave back much of the gain after managements cautious tone. Traders are split between seeing a turnaround and potential short squeeze, and questioning whether growth is sustainable given weak underlying trends and the lack of recent buybacks.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Goldman Sachs upgrade to Buy and a wave of analyst target increases are drawing attention, building on Zetas strong quarterly results and raised guidance. Traders are largely bullish on the breakout, though some remain wary of volatility and resistance after the earnings-related swings.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is under pressure after its Q3 report and analyst target cuts, as traders focus on delayed satellite launches, the slower path to commercial service, and the execution and funding risks of developing Blacklift. Bulls point to Japan and government funding and the companys partnerships, while bears argue launch delays and cash needs weaken the growth case.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly revenue beat and raised sales outlook were overshadowed by narrowing gross margins and unchanged EBITDA guidance, sparking a sharp selloff as traders questioned whether growth is translating into profitability; debt concerns add to the bearish case. Some traders call the drop an overreaction to a strong quarter and are buying the dip, while others see the margin pressure as a more serious warning.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,957,873.22986632. The last known price of Zcash is 1,170.00468254 USD and is down -4.93 over the last 24 hours. It is currently trading on 669 active market(s) with $1,123,501,581.28 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention after a sharp pullback that traders say broke support, with some linking the move to crypto-wide liquidations and risk-off sentiment while others view it as a buying opportunity after the coins earlier rally. The discussion is split between bearish calls for further losses and holders expecting a rebound.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Globals strong quarterly results and higher full-year outlook are driving attention, alongside its proposed expansion into off-grid power for AI data centers. Traders broadly praise the LNG performance but debate whether the long-term AI push and its spending distract from nearer-term LNG profits, while some point to short-selling pressure to explain the muted share-price reaction.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice 

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy

Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NBIX vs. GRDN: Which Stock Is the Better Value Option?

Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) Capsules

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) Capsules Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) CapsulesPR...

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall CongressPR NewswireSAN DIEGO, Nov. 3, 2026 SAN DIEGO, Nov. 3...

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View

Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +29.53% and +8.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results Neurocrine Biosciences Reports Third-Quarter 2026 Financial ResultsPR NewswireSAN DIEGO, Nov. 2, 2026 Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 BillionINGREZZA (valbenazine) 2026 Net Sales Guidance Raised to...

• Reported GAAP EPS of $3.29 up 51.61% YoY
• Reported revenue of $1.12B up 41.24% YoY

Neurocrine Biosciences' earnings were below prior-year figures with an equity-investment loss; VYKAT XR has a potential FDA safety signal under evaluation, and four customers represent over 90% of gross product sales.

Neurocrine Biosciences' Q3 INGREZZA sales increased alongside record new prescriptions; the Soleno acquisition added VYKAT XR, while Phase 2 studies initiated in Alzheimers cognition, schizophrenia, and pediatric CAH.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Neurocrine Biosciences gained VYKAT XR through its $2.9-billion acquisition of Soleno Therapeutics, completed in May.</li><li>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug.</li><li>In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure with Vykat XR use, along with concerns about clinical-trial data.</li></ul><p>Shares of Neurocrine Biosciences closed 3% lower on Wednesday and further slipped 1% after-hours after the Foundation for Prader-Willi Research (FPWR) recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on its drug VYKAT XR for fluid retention and related heart or breathing problems.</p><p>FPWR blog from Monday outlines practical steps for real-world use of the drug, the first FDA-approved treatment for extreme hunger (hyperphagia) in PWS patients aged four and older. FPWR further advises families to review the full prescribing information and consult PWS specialists so the potential benefits of reduced hyperphagia can be weighed carefully against the risks.</p><p>Since Vykat XR’s March 2025 launch, more than 800 people have received prescriptions. The medicine can help control appetite but may cause edema that, in some cases, has been linked to serious complications, according to experts.</p><h2 class="st-heading-2">Heightened Focus On Safety Signals</h2><p>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug. Many of those individuals already had obesity, multiple medications, or untreated sleep apnea. The foundation stresses that PWS itself carries elevated baseline risks, so a direct link is not always clear. Still, it recommends safety tests before starting treatment, ongoing checks for swelling or breathing changes, and care from physicians experienced with the syndrome.</p><h2 class="st-heading-2">Neurocrine Adds Vykat XR</h2><p>Neurocrine Biosciences gained VYKAT XR through its $2.9 billion acquisition of Soleno Therapeutics, completed in May. Soleno developed and launched the once-daily pill.</p><p>While still under Soleno, the drug faced scrutiny. In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure, along with concerns about clinical-trial data. The following month, Soleno disclosed the death of a 17-year-old patient who had been taking the medicine, though the company and treating physician assessed the death as unrelated to the drug. Investor lawsuits later claimed Soleno had downplayed fluid-retention signals.</p><h2 class="st-heading-2">Broader Impact On PWS Pipeline</h2><p>Safety worries have slowed other PWS programs. Aardvark Therapeutics paused its late-stage trial of ARD-101 last year after cardiac observations in healthy volunteers, and the FDA later placed a clinical hold. Years earlier, Zafgen ended development of beloranib after patient deaths linked to blood clots. Acadia Pharmaceuticals also discontinued its candidate after a failed efficacy study.</p><h2 class="st-heading-2">How Did NBIX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NBIX stayed within ‘bearish’ territory while message volume stayed at ‘normal’ levels.</p><p>A Stocktwits user highlighted that no clear link has been established between the drug’s use and the negative side effects.</p><p><stembedurl>https://www.stocktwits.com/GoIrish1776/message/661644013</stembedurl></p><p>“I always thought vykat/soleno was a bad drug and investment,” another user wrote.</p><p><stembedurl>https://www.stocktwits.com/outlawinvestor1/message/661718610</stembedurl></p><p><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://stocktwits.comhttps://stocktwits.com/symbol/NBIX/symbol/NBIX">NBIX stock</a> has gained 10% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-cars-facing-more-demand-than-stock-buyers-face-extended-waits-for-base-model-3-model-y-and-cybertruck/cZo8SNZRJWH">Tesla Cars Facing More Demand Than Stock? Buyers Face Extended Waits For Base Model 3, Model Y And Cybertruck</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Neurocrine Biosciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Safety Warnings

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems. 


American Century ETF Trust - Avantis U.S. Equity ETF

JPMorgan Active Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$2.06	--	--	N/A
Q3 '26	$1.91	$1.96	2.61%	BEAT
Q2 '26	$1.66	$1.39	-16.38%	MISSED
Q1 '26	$1.22	$1.91	57.05%	BEAT
Q4 '25	$1.80	$1.48	-17.97%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

NBIX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings